Mutations in the OPHN1 gene (Xq12) are associated withX-linked mental retardation with subtle facial dysmorphism and cerebellaranomalies, including hypoplasia of the vermis, expansion of the cisterna magna,and retrocerebellar cysts. Phenotypic features can include neonatal hypotoniawith motor delay but no obvious ataxia, marked strabismus, early-onset complexpartial seizures, and moderate to severe intellectual disability. Other affected individualswith OPHN1 mutations are reported tohave moderate to severe intellectual disability associated with enlargement of thelateral ventricles and cerebellar hypoplasia, seizures, ataxia, strabismus, andhypogenitalism with cryptorchidism, hypoplastic scrotum, and microphallus.
Facial features associated with OPHN1 mutations include mild facialdysmorphism with long face, prominent forehead, deep-set eyes, markedinfraorbital creases, strabismus, short or upturned philtrum, and large ears. Obligatefemale carriers have been reported to show subtle facial changes and/or reducedcerebellar size in some cases.
In one study, four different novelmutations were identified in the OPHN1gene: two mutations were found in a group of 17 unrelated males with mental retardationand known cerebellar anomalies (12%) and two mutations were found in a group of196 unrelated males with X-linked intellectual disability without previous brainimaging studies (1%). Retrospective imaging studies, when possible, detectedcerebellar hypoplasia in the latter patients.
Both point mutations and deletionshave been reported in the OPHN1 gene.
For patients with suspected XLMR with cerebellar hypoplasia and distinctive facial appearance, sequence analysis is recommended as the first step in mutation identification. For patients in whom mutations are not identified by full gene sequencing, deletion/duplication analysis is appropriate.
Click here for the OMIM summary on this condition.
This test is indicated for:
- Confirmation of a clinical diagnosis of XLMR with cerebellar hypoplasia and distinctive facial appearance
- Carrier testing in adult females with a family history of XLMR with cerebellar hypoplasia and distinctive facial appearance
Clinical Sensitivity: Unknown. Mutations in the promoter region, some mutations in the introns and other regulatory element mutations cannot be detected by this analysis. Large deletions will not be detected by this analysis. Results of molecular analysis should be interpreted in the context of the patient's biochemical phenotype.
Analytical Sensitivity: ~99%
Isolation using the Perkin Elmer™Chemagen™ Chemagen™ Automated Extraction method or Qiagen™ Puregene kit for DNA extraction is recommended.
Infants and Young Children (<2 years of age): 2-3 ml
Children > 2 years of age to 10 years old: 3-5 ml
Older Children & Adults: 5-10 ml
Autopsy: 2-3 ml unclotted cord or cardiac blood
Orangene™ Saliva Collection Kit used according to manufacturer instructions. Please contact EGL for a Saliva Collection Kit for patients that cannot provide a blood sample.
Submit copies of diagnostic biochemical test results with the sample, if appropriate. Contact the laboratory if further information is needed.
Sequence analysis is required before deletion/duplication analysis by targeted CGH array. If sequencing is performed outside of EGL Genetics, please submit a copy of the sequencing report with the test requisition.
- Deletion/duplication analysis of the OPHN1 gene by CGH array is available for those individuals in whom sequence analysis is negative (YS).
- A CGH array-based test for deletion/duplication analysis of 64 different X-linked intellectual disability genes is available (OL).
- Custom diagnostic mutation analysis (KM) is available to family members if mutations are identified by targeted mutation testing or sequencing analysis.
- Prenatal testing is available to adult females who are confirmed carriers of mutations. Please contact the laboratory genetic counselor to discuss appropriate testing prior to collecting a prenatal specimen.